VNDA
insider transactionsVanda Pharmaceuticals Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-344.3K
0 buy · 344.3K sell
Net value · 365d
-$2.8M
$0 in · $2.8M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
6
0 buy · 344.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
41.6K sh
Own +35%
-
Grant·A
Director
$0
41.6K sh
Own +58%
-
Grant·A
SVP, GC and Secretary
$0
80.0K sh
Own +267%
-
Grant·A
Director
$0
41.6K sh
Own +45%
-
Grant·A
Director
$0
41.6K sh
Own +73%
-
Grant·A
Director
$0
41.6K sh
Own +23%
-
Grant·A
Director
$0
41.6K sh
Own +34%
-
Other·G
Director
$0
25.8K sh
Own -27%
-
Grant·A
Director
$0
57.1K sh
Own New
-
Sell·S
SVP, Chief Marketing Officer
$254.6K
30.8K sh · $8.27
Own -8%
-
Sell·S
SVP & General Counsel
$350.8K
42.4K sh · $8.27
Own -10%
-
Sell·S
Mihael Hristos Polymeropoulos KEY
President and CEO
$1.3M
156.2K sh · $8.17
Own -5%
-
Sell·S
SVP, CFO & Treasurer
$350.8K
42.4K sh · $8.27
Own -9%
-
Sell·S
SVP, Business Development
$350.7K
42.4K sh · $8.27
Own -8%
-
Sell·S
Director
$240.9K
30.0K sh · $8.03
Own -24%
-
Grant·A
SVP, Chief Marketing Officer
$0
125.0K sh
Own +52%
-
Grant·A
SVP & General Counsel
$0
125.0K sh
Own +42%
-
Grant·A
Mihael Hristos Polymeropoulos KEY
President and CEO
$0
525.0K sh
Own +22%
-
Grant·A
SVP, CFO & Treasurer
$0
125.0K sh
Own +38%
-
Grant·A
SVP, Business Development
$0
125.0K sh
Own +30%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Anne Sempowski Ward | Grant A | 41.6K | $0 |
| Jun 4, 2026 | Stephen Ray Mitchell | Grant A | 41.6K | $0 |
| Jun 4, 2026 | McGuire Daniel Patrick | Grant A | 80.0K | $0 |
| Jun 4, 2026 | Tage Honore | Grant A | 41.6K | $0 |
| Jun 4, 2026 | Charles Cliff Duncan | Grant A | 41.6K | $0 |
| Jun 4, 2026 | Richard W Dugan | Grant A | 41.6K | $0 |
| Jun 4, 2026 | Phaedra Chrousos | Grant A | 41.6K | $0 |
| May 18, 2026 | Stephen Ray Mitchell | Other G | 25.8K | $0 |
| Apr 22, 2026 | Charles Cliff Duncan | Grant A | 57.1K | $0 |
| Mar 2, 2026 | Joakim Wijkstrom | Sell S | 30.8K | $254.6K |
| Mar 2, 2026 | Timothy Williams | Sell S | 42.4K | $350.8K |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos KEY | Sell S | 156.2K | $1.3M |
| Mar 2, 2026 | Kevin Patrick Moran KEY | Sell S | 42.4K | $350.8K |
| Mar 2, 2026 | Gunther Birznieks | Sell S | 42.4K | $350.7K |
| Feb 23, 2026 | Tage Honore | Sell S | 30.0K | $240.9K |
| Feb 18, 2026 | Joakim Wijkstrom | Grant A | 125.0K | $0 |
| Feb 18, 2026 | Timothy Williams | Grant A | 125.0K | $0 |
| Feb 18, 2026 | Mihael Hristos Polymeropoulos KEY | Grant A | 525.0K | $0 |
| Feb 18, 2026 | Kevin Patrick Moran KEY | Grant A | 125.0K | $0 |
| Feb 18, 2026 | Gunther Birznieks | Grant A | 125.0K | $0 |
About VNDA insider trading
This page tracks insider transactions for Vanda Pharmaceuticals Inc. (VNDA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.